MX2010008633A - Ruptura de tolerancia inmunologica con un aminoacido no natural geneticamente codificado. - Google Patents

Ruptura de tolerancia inmunologica con un aminoacido no natural geneticamente codificado.

Info

Publication number
MX2010008633A
MX2010008633A MX2010008633A MX2010008633A MX2010008633A MX 2010008633 A MX2010008633 A MX 2010008633A MX 2010008633 A MX2010008633 A MX 2010008633A MX 2010008633 A MX2010008633 A MX 2010008633A MX 2010008633 A MX2010008633 A MX 2010008633A
Authority
MX
Mexico
Prior art keywords
amino acid
unnatural amino
genetically encoded
immunological tolerance
target moiety
Prior art date
Application number
MX2010008633A
Other languages
English (en)
Inventor
Jan Grunewald
Meng-Lin Tsao
Roshan Perea
Richard A Lerner
Vaughn V Smider
Peter G Schultz
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MX2010008633A publication Critical patent/MX2010008633A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención comprende métodos y composiciones para producir y/o mejorar una respuesta inmunológica en un sujeto contra una porción objetivo tal como una porción relacionada a enfermedad, por administración de una version antigénica de la porción objetivo que tiene uno o más aminoácidos no naturales y/o por administración de un anticuerpo contra una versión de una porción objetivo que tiene uno o más aminoácidos no naturales, este anticuerpo es de reacción cruzada con la porción objetivo natural.
MX2010008633A 2008-02-08 2009-02-07 Ruptura de tolerancia inmunologica con un aminoacido no natural geneticamente codificado. MX2010008633A (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US6514708P 2008-02-08 2008-02-08
US6514808P 2008-02-08 2008-02-08
US6551508P 2008-02-12 2008-02-12
US6559008P 2008-02-12 2008-02-12
US13594708P 2008-07-25 2008-07-25
US13596908P 2008-07-25 2008-07-25
US13767608P 2008-07-31 2008-07-31
US13763508P 2008-07-31 2008-07-31
US20394708P 2008-12-29 2008-12-29
US20394808P 2008-12-29 2008-12-29
PCT/US2009/000813 WO2009099672A2 (en) 2008-02-08 2009-02-07 Breaking immunological tolerance with a genetically encoded unnatural amino acid

Publications (1)

Publication Number Publication Date
MX2010008633A true MX2010008633A (es) 2010-09-30

Family

ID=40952613

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008633A MX2010008633A (es) 2008-02-08 2009-02-07 Ruptura de tolerancia inmunologica con un aminoacido no natural geneticamente codificado.

Country Status (11)

Country Link
US (2) US20110052525A1 (es)
EP (1) EP2249865A4 (es)
JP (1) JP2011514322A (es)
KR (1) KR20100125290A (es)
CN (1) CN101970005A (es)
AU (1) AU2009210677A1 (es)
BR (1) BRPI0906388A2 (es)
CA (1) CA2712080A1 (es)
IL (1) IL207013A0 (es)
MX (1) MX2010008633A (es)
WO (1) WO2009099672A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1456360B1 (en) * 2001-04-19 2015-06-03 The Scripps Research Institute Methods and composition for the production of orthoganal trna-aminoacyltrna synthetase pairs
CN103215228A (zh) 2003-04-17 2013-07-24 斯克利普斯研究院 扩展真核生物遗传密码
US7638297B2 (en) * 2003-07-07 2009-12-29 The Scripps Research Institute Compositions of orthogonal lysyl-tRNA and aminoacyl-tRNA synthetase pairs and uses thereof
EP2337846B1 (en) 2008-09-26 2018-01-17 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
CN104955480A (zh) 2013-01-25 2015-09-30 西蒙有限公司 用于选择性减少循环的生物活性可溶性tnf的组合物以及用于治疗tnf介导的疾病的方法
CN103183734B (zh) * 2013-02-21 2016-01-20 中国药科大学 含有非天然氨基酸的突变蛋白及其应用
JP7297408B2 (ja) 2015-02-06 2023-06-26 セル アイディーエックス， インコーポレイテッド 抗原をカップリングさせた免疫試薬
CN104761631A (zh) * 2015-04-15 2015-07-08 中国药科大学 多位点引入对硝基苯丙氨酸的人肿瘤坏死因子-α
JP6998217B2 (ja) 2015-06-25 2022-02-10 ダウ グローバル テクノロジーズ エルエルシー 低ヘキサン抽出物及び低密度を有するエチレン系ポリマー
US10400046B2 (en) 2015-06-25 2019-09-03 Joseph J. Matsko Portable powered paint system
EP3313894B1 (en) 2015-06-25 2019-12-18 Dow Global Technologies LLC Improved process to make tubular ethylene based polymers with high g' and broad mwd
JP7510740B2 (ja) 2015-06-25 2024-07-04 ダウ グローバル テクノロジーズ エルエルシー 低ヘキサン抽出物を有するエチレン系ポリマー
CN107743496B (zh) 2015-06-25 2020-06-16 陶氏环球技术有限责任公司 制备具有高熔融强度的管状乙烯类聚合物的改进方法
CN106929482A (zh) * 2015-12-31 2017-07-07 北京大学 定点突变的流感病毒、其活疫苗及其制备方法和应用
CN107033232A (zh) * 2016-02-04 2017-08-11 上海亨臻实业有限公司 一种低生物活性的肿瘤坏死因子α突变蛋白及其制法和用途
CN107459580A (zh) * 2016-06-06 2017-12-12 易金阳 一种利用酵母菌表达含有穿膜肽的寡肽‑1（egf）创新制备工艺
US20190233876A1 (en) * 2016-07-18 2019-08-01 Cell Idx, Inc. Antigen-coupled hybridization reagents
CN109748952B (zh) * 2018-05-02 2020-09-15 中国药科大学 辅助性表位肽及其应用
CN112611864B (zh) * 2020-12-03 2024-03-12 重庆市畜牧科学院 筛分病菌模型的***及筛分方法
WO2023025147A1 (zh) * 2021-08-23 2023-03-02 南通壹宸生物医药科技有限公司 抗原表位修饰

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1456360B1 (en) * 2001-04-19 2015-06-03 The Scripps Research Institute Methods and composition for the production of orthoganal trna-aminoacyltrna synthetase pairs
SG160203A1 (en) * 2002-10-16 2010-04-29 Scripps Research Inst Glycoprotein synthesis
CA2508939A1 (en) * 2002-12-22 2004-07-15 The Scripps Research Institute Protein arrays
CN103215228A (zh) * 2003-04-17 2013-07-24 斯克利普斯研究院 扩展真核生物遗传密码
EP2392923B1 (en) * 2003-06-18 2014-05-21 The Scripps Research Institute Method of producing proteins comprising unnatural amino acid
US20060160175A1 (en) * 2003-07-07 2006-07-20 The Scripps Research Institute Compositions of orthogonal leucyl-trna and aminoacyl-trna synthetase pairs and uses thereof
US7527943B2 (en) * 2003-07-07 2009-05-05 The Scripps Research Institute Compositions of orthogonal glutamyl-tRNA and aminoacyl-tRNA synthetase pairs and uses thereof
US7638297B2 (en) * 2003-07-07 2009-12-29 The Scripps Research Institute Compositions of orthogonal lysyl-tRNA and aminoacyl-tRNA synthetase pairs and uses thereof
CA2541166A1 (en) * 2003-10-14 2005-04-28 The Scripps Research Institute Site-specific incorporation of redox active amino acids into proteins
AU2004321117B2 (en) * 2003-12-18 2010-09-02 The Scripps Research Institute Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells
JP2008500050A (ja) * 2004-05-25 2008-01-10 ザ スクリップス リサーチ インスティテュート 結晶構造決定のための重原子含有非天然アミノ酸の部位特異的蛋白質組込み
AU2005327906B2 (en) * 2004-07-21 2010-05-13 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
WO2006034410A2 (en) * 2004-09-21 2006-03-30 The Scripps Resarch Institute Adding photoregulated amino acids to the genetic code
ES2519444T3 (es) * 2004-09-21 2014-11-07 The Scripps Research Institute Incorporación in vivo de alquinil aminoácidos a proteínas en eubacterias
EP1794312A4 (en) * 2004-09-22 2009-08-12 Scripps Research Inst LOCAL LABELING OF PROTEINS FOR NMR STUDIES
JP2008516637A (ja) * 2004-10-20 2008-05-22 ザ スクリップス リサーチ インスティテュート 真正細菌へのｎ−アセチルガラクトサミンアミノ酸のインビボ部位特異的組込み
AU2006304110B2 (en) * 2005-10-12 2012-02-02 The Scripps Research Institute Selective posttranslational modification of phage-displayed polypeptides
WO2007075438A2 (en) * 2005-12-15 2007-07-05 Codon Devices, Inc. Polypeptides comprising unnatural amino acids, methods for their production and uses therefor
AU2007215566A1 (en) 2006-01-19 2007-08-23 Ambrx, Inc. Non-natural amino acid polypeptides having modulated immunogenicity
US8198044B2 (en) * 2006-03-09 2012-06-12 The Scripps Research Institute Systems for the expression of orthogonal translation components eubacterial host cells
EP1994165B1 (en) * 2006-03-16 2014-11-05 The Scripps Research Institute Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine
US7632492B2 (en) * 2006-05-02 2009-12-15 Allozyne, Inc. Modified human interferon-β polypeptides

Also Published As

Publication number Publication date
AU2009210677A1 (en) 2009-08-13
US8318172B2 (en) 2012-11-27
US20110052525A1 (en) 2011-03-03
EP2249865A2 (en) 2010-11-17
WO2009099672A3 (en) 2009-11-12
US20090263376A1 (en) 2009-10-22
CA2712080A1 (en) 2009-08-13
IL207013A0 (en) 2010-12-30
KR20100125290A (ko) 2010-11-30
WO2009099672A2 (en) 2009-08-13
BRPI0906388A2 (pt) 2015-07-07
EP2249865A4 (en) 2012-04-04
CN101970005A (zh) 2011-02-09
JP2011514322A (ja) 2011-05-06

Similar Documents

Publication Publication Date Title
MX2010008633A (es) Ruptura de tolerancia inmunologica con un aminoacido no natural geneticamente codificado.
AU2017204797B2 (en) Antibodies with modified isoelectric points
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
BR122021020829B8 (pt) Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
IL196893A0 (en) Site specific incorporation of non-natural amino acids by vertebrate cells
MX2014007665A (es) Composiciones y metodos para anticuerpos dirigidos al factor p.
MX2009000520A (es) Metodos para producir combustibles y solventes.
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
WO2007120932A3 (en) Expression of o-glycosylated therapeutic proteins in prokaryotic microorganisms
BRPI0817299A8 (pt) vacinas e componentes de vacina para inibição de células microbianas
WO2008097866A3 (en) Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
WO2008000028A8 (en) Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease
WO2011004028A3 (en) Tlr3 binding agents
SG165339A1 (en) Incorporation of non-naturally encoded amino acids into proteins
MX2009002526A (es) Transcripcion de tarn supresor en celulas de vertebrados.
NZ601793A (en) Methods and compositions for diagnosis and treatment of cancer
WO2006019876A3 (en) Production of fusion proteins by cell-free protein synthesis
WO2010065876A3 (en) Methods and compositions related to th-1 dendritic cells
MX351499B (es) Anticuerpos estables y solubles.
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2009137778A3 (en) Methods and compositions for genetically engineering clostridia species
MA32388B1 (fr) Immunomodulation par des inhibiteurs d'iap
MX2010001237A (es) Nuevos anticuerpos.

Legal Events

Date Code Title Description
FG Grant or registration